The White House on Feb. 5 launched TrumpRx, a direct-to-consumer website aimed at reducing prescription drug costs by linking patients to manufacturer discounts — but many listed drugs are available for less elsewhere.
The site primarily targets uninsured patients or those lacking coverage for high-cost drugs such as GLP-1s and fertility treatments. TrumpRx even warns users, “If you have insurance, check your copay first — it may be even lower,” according to a Feb. 6 report from The New York Times.
The platform lists 43 brand-name medications and directs users to drugmaker websites or provides printable coupons. At launch, five companies participated: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer.
Discounted drugs on TrumpRx include Wegovy pills at $149 and Zepbound at $299 — prices marketed as steep reductions from retail list prices. But many of these medications are already available for less through insurance, generics or third-party tools such as GoodRx, according to a Feb. 6 report from CNBC.
Novo Nordisk, for example, priced Ozempic at $350 per month through TrumpRx. Yet in Medicare Part D, average brand-name drug discounts reach 40% off list prices, and Medicaid discounts exceed 75%, CNBC reported.
Although the platform may offer savings for some cash-paying patients, pricing comparisons suggest most insured Americans are still likely to find lower costs elsewhere.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
